GB717008A — Morphine derivative
Assigned to Individual · Expires 1954-10-20 · 72y expired
What this patent protects
The invention comprises 14-hydroxy-dihydromorphinone and its salts, and preparation thereof by demethylating 14-hydroxy-dihydrocodeinone. In the example concentrated hydrobromic acid is used, the cooled diluted product being made alkaline and extracted with a water-immiscible liq…
USPTO Abstract
The invention comprises 14-hydroxy-dihydromorphinone and its salts, and preparation thereof by demethylating 14-hydroxy-dihydrocodeinone. In the example concentrated hydrobromic acid is used, the cooled diluted product being made alkaline and extracted with a water-immiscible liquid (e.g. chloroform) to remove unwanted material; the aqueous phase is acidified, ammonia is added and the desired product extracted with ether and crystallized from ethanol. Other demethylating agents are specified. The product forms salts with acids, e.g. a hydrochloride, hydrobromide, hydriodide, sulphate, orthophosphate, metaphosphate, nitrite, nitrate, bitartrate, salicylate, terephthalate, acetate, propionate, phthalate, benzoate, camphorsulphonate and citrate. It may be remethylated to 14-hydroxy-dihydrocodeinone.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.